相关实验视频

Updated: Jun 13, 2025

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

纳米/生物医学的尖端进展:关于转化血栓解压疗法的审查

Chia-Hung Liu¹, Lekshmi Rethi², Pei-Wei Weng³

¹Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 11031, Taiwan; TMU Research Center of Urology and Kidney, Taipei Medical University, 250 Wu-Hsing Street, Taipei 11031, Taiwan; Department of Urology, Shuang Ho Hospital, Taipei Medical University, 291 Zhongzheng Road, Zhonghe District, New Taipei City 23561, Taiwan.

Biochemical pharmacology

|September 9, 2024

概括

纳米医学通过将等离子素激活剂 (PA) 封装在向的纳米载体中来增强血栓溶解. 这种方法可以提高治疗效率和治疗血栓性疾病的安全性,如中风和心脏病发作.

科学领域:

心血管研究研究心血管研究
纳米医学是一种纳米医学.
生物技术是生物技术.

背景情况:

血栓阻塞会导致严重的心血管疾病,如中风和心肌梗塞.
使用等离子体激活剂 (PA) 的当前血栓溶解面临限制,包括快速排泄和出血风险.
纳米医学提供了一个有希望的策略,通过提高PA的输送和有效性来克服这些局限性.

研究的目的:

审查静脉和动脉血栓的病理生理学.
为提供已批准用于血栓状况的等离子原激活剂 (PA) 的概述.
探索纳米医学策略用于向的血栓解压疗法.

主要方法:

关于血栓溶解和纳米载体系统的当前文献的综述.
分析各种向的纳米载体 (脂质,聚合物,无机,生物) 用于PA输送.
讨论超声波辅助索诺血栓溶解和微泡技术.

主要成果:

纳米医学在临床前和临床研究中显著改善了PA的输送,疗效和安全性.
向的纳米载体证明了PA的精确传递到血栓部位.
超声中介的Sono血栓溶解显示了改善的治疗结果.

结论:

纳米医学为严重的血栓状况提供了精确有效的治疗方法.
向的纳米基载体为改善患者治疗结果和减少治疗血栓性疾病并发症提供了一条途径.
纳米载体系统的进一步开发为推进血栓解压疗法具有重大潜力.

关键词:

生物医学是生物医学.纳米医学是一种纳米医学.一次性中风,中风.血栓溶解是一种血栓溶解.

更多相关视频

Prehospital Thrombolysis: A Manual from Berlin

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...